Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake
- Sponsor
- University Hospital, Basel, Switzerland
- Study ID
- NCT03141632
- Phase
- PHASE2
- Status
- Completed
Conditions
- Thirst
- Water-Electrolyte Imbalance
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Accepted
Interventions
- Dulaglutide — DRUGEvaluation visit with assessment of fluid intake
- Placebo — OTHEREvaluation visit with assessment of fluid intake
Study Details
The aim of this study is to elucidate whether GLP-1 analogues influence not only appetite but also thirst perception. It is hypothesized that GLP-1 analogues reduce fluid intake in healthy volunteers compared to Placebo.
Key Dates
- Start date
- Oct 17, 2016
- Status verified
- Oct 2017
- Primary completion
- May 31, 2017
- Completion
- May 12, 2017
Study Design
- Enrollment
- 17 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Active Comparator: DulaglutideDulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
- Placebo Comparator: Placebo0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.
Primary Outcome Measure
Fluid intake [ Time Frame: 8 hours ]